Clik here to view.
End Duchenne Tour Recap: Palo Alto, CA
PPMD headed to Palo Alto, CA for our End Duchenne Tour stop on November 3, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources...
View ArticleFibroGen Receives U.S. FDA Orphan Drug Designation for Pamrevlumab for the...
FibroGen announced that FDA has granted Orphan Drug Designation for the company’s anti-CTGF antibody, pamrevlumab, for the treatment of people with Duchenne. According to their press release, all 21...
View ArticleFibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial
FibroGen, Inc. announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients...
View ArticleRecently Reported Updates from PPMD’s 2021 Virtual Annual Conference
PPMD’s 2021 Virtual Annual Conference: Recently Reported Updates As a new addition to PPMD’s 2021 Virtual Conference, PPMD invited industry partners to share new data with the community live during the...
View ArticleWATCH: FibroGen DMD Pamrevlumab Phase 3 Clinical Studies Highlight (Webinar...
FibroGen joined PPMD for a webinar on February 2, 2022. During the webinar, FibroGen discussed the clinical rationale for the use of Pamrevlumab by highlighting its Phase 2 study in non-ambulatory...
View ArticleFibroGen Announces Topline Data from Phase 3 LELANTOS-1 Study
This morning, FibroGen announced topline data from the Phase 3 LELANTOS-1 study of pamrevlumab, their investigational monoclonal antibody, for non-ambulatory patients with Duchenne muscular dystrophy....
View ArticleFibroGen Announces Topline Data from Phase 3 LELANTOS-2 Study
FibroGen has announced topline results of the Phase 3 LELANTOS-2 trial of pamrevlumab, their investigational anti-fibrotic monoclonal antibody, for ambulatory patients with Duchenne muscular dystrophy....
View ArticleFibroGen announces discontinuation of LELANTOS-2 Open Label Extension
PPMD has recently learned that FibroGen has discontinued the LELANTOS-2 Open Label Extension. This news follows the August 2023 release of negative topline results of the Phase 3 LELANTOS-2 trial of...
View Article
